Literature DB >> 10799893

The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A.

B D Wines1, M S Powell, P W Parren, N Barnes, P M Hogarth.   

Abstract

The CH2-CH3 interface of the IgG Fc domain contains the binding sites for a number of Fc receptors including Staphylococcal protein A and the neonatal Fc receptor (FcRn). It has recently been proposed that the CH2-CH3 interface also contains the principal binding site for an isoform of the low affinity IgG Fc receptor II (Fc gamma RIIb). The Fc gamma RI and Fc gamma RII binding sites have previously been mapped to the lower hinge and the adjacent surface of the CH2 domain although contributions of the CH2-CH3 interface to binding have been suggested. This study addresses the question whether the CH2-CH3 interface plays a role in the interaction of IgG with Fc gamma RI and Fc gamma RIIa. We demonstrate that recombinant soluble murine Fc gamma RI and human Fc gamma RIIa did not compete with protein A and FcRn for binding to IgG, and that the CH2-CH3 interface therefore appears not to be involved in Fc gamma RI and Fc gamma RIIa binding. The importance of the lower hinge was confirmed by introducing mutations in the proposed binding site (LL234,235AA) which abrogated binding of recombinant soluble Fc gamma RIIa to human IgG1. We conclude that the lower hinge and the adjacent region of the CH2 domain of IgG Fc is critical for the interaction between Fc gamma RIIa and human IgG, whereas contributions of the CH2-CH3 interface appear to be insignificant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799893     DOI: 10.4049/jimmunol.164.10.5313

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques.

Authors:  Maren Q DeGottardi; Afam A Okoye; Mukta Vaidya; Aarthi Talla; Audrie L Konfe; Matthew D Reyes; Joseph A Clock; Derick M Duell; Alfred W Legasse; Amit Sabnis; Byung S Park; Michael K Axthelm; Jacob D Estes; Keith A Reiman; Rafick-Pierre Sekaly; Louis J Picker
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

2.  Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.

Authors:  Philipp A Ilinykh; Kai Huang; Rodrigo I Santos; Pavlo Gilchuk; Bronwyn M Gunn; Marcus M Karim; Jenny Liang; Mallorie E Fouch; Edgar Davidson; Diptiben V Parekh; James B Kimble; Colette A Pietzsch; Michelle Meyer; Natalia A Kuzmina; Larry Zeitlin; Erica Ollmann Saphire; Galit Alter; James E Crowe; Alexander Bukreyev
Journal:  Cell Host Microbe       Date:  2020-04-21       Impact factor: 21.023

Review 3.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Authors:  Michal Pyzik; Timo Rath; Wayne I Lencer; Kristi Baker; Richard S Blumberg
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

4.  IgG2m4, an engineered antibody isotype with reduced Fc function.

Authors:  Zhiqiang An; Gail Forrest; Renee Moore; Michael Cukan; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jing Zhang Zhao; Ping Lu; Jin Hua; Christopher R Gibson; Barrett R Harvey; Donna Montgomery; Dennis Zaller; Fubao Wang; William Strohl
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

5.  Dependence of antibody-mediated presentation of antigen on FcRn.

Authors:  Shuo-Wang Qiao; Kanna Kobayashi; Finn-Eirik Johansen; Ludvig M Sollid; Jan Terje Andersen; Edgar Milford; Derry C Roopenian; Wayne I Lencer; Richard S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-01       Impact factor: 11.205

6.  Boosting antibody developability through rational sequence optimization.

Authors:  Daniel Seeliger; Patrick Schulz; Tobias Litzenburger; Julia Spitz; Stefan Hoerer; Michaela Blech; Barbara Enenkel; Joey M Studts; Patrick Garidel; Anne R Karow
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo.

Authors:  Kirstin A Zettlitz; Richard Tavaré; Scott M Knowles; Kristopher K Steward; John M Timmerman; Anna M Wu
Journal:  Clin Cancer Res       Date:  2017-09-19       Impact factor: 12.531

9.  Human mAbs to Staphylococcus aureus IsdA Provide Protection Through Both Heme-Blocking and Fc-Mediated Mechanisms.

Authors:  Monique R Bennett; Robin G Bombardi; Nurgun Kose; Erica H Parrish; Marcus B Nagel; Robert A Petit; Timothy D Read; Kevin L Schey; Isaac P Thomsen; Eric P Skaar; James E Crowe
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

10.  A monoclonal antibody that recognizes the E domain of staphylococcal protein A.

Authors:  Hwan Keun Kim; Carla Emolo; Dominique Missiakas; Olaf Schneewind
Journal:  Vaccine       Date:  2013-11-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.